Please enter
CQ 6/29/06

**Amendment to the Claims:**

Claims 1-62 (Canceled)

63. (Currently amended) A transgenic mouse whose genome comprises a null endogenous lymphoid specific GPCR allele~~; wherein said null allele comprises exogenous DNA, said exogenous DNA comprising a gene encoding a visible marker, wherein said gene is capable of expression in the spleen~~.

64. (Previously presented) The transgenic mouse of claim 63, wherein the mouse is homozygous for said null allele.

65. (Previously presented) The transgenic mouse of claim 64, wherein the mouse exhibits, relative to a wild-control mouse, lymphocyte cellular infiltration of liver tissue and/or pancreatic tissue.

66. (Previously presented) The transgenic mouse of claim 64, wherein the mouse exhibits, relative to a wild-type control mouse, cellular infiltration of stomach tissue by at least one of the following types of cells: lymphocytes, granulocytes or plasma cells.

67. (Previously presented) A cell or tissue isolated from the transgenic mouse of claim 63.

68. (Previously presented) The transgenic mouse of claim 63, wherein the mouse is heterozygous for said null allele.

69. (Previously presented) A cell or tissue isolated from the transgenic mouse of claim 68.

70. (Previously presented) A method of producing a transgenic mouse of claim 63, the method comprising:

(a) introducing a targeting construct capable of disrupting the endogenous lymphoid specific GPCR gene into a murine embryonic stem cell;

(b) selecting for the murine embryonic stem cell that has undergone homologous recombination;

(c) introducing the murine embryonic stem cell selected for in step (b) into a mouse blastocyst;

(d) implanting the resulting blastocyst into a pseudopregnant mouse, wherein the resultant mouse gives birth to a chimeric mouse; and

(e) breeding the chimeric mouse to produce the transgenic mouse.

71. (Canceled)